
Gerrit Storm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9238515/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endosomal escape pathways for delivery of biologicals. Journal of Controlled Release, 2011, 151, 220-228.	9.9	1,278
2	Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 2012, 161, 175-187.	9.9	1,131
3	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 2017, 108, 25-38.	13.7	881
4	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Research, 2004, 32, e149-e149.	14.5	800
5	Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharmaceutical Research, 2010, 27, 2569-2589.	3.5	791
6	Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 1995, 17, 31-48.	13.7	788
7	Theranostic Nanomedicine. Accounts of Chemical Research, 2011, 44, 1029-1038.	15.6	765
8	Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Frontiers in Pharmacology, 2018, 9, 790.	3.5	586
9	Sheddable Coatings for Long-Circulating Nanoparticles. Pharmaceutical Research, 2008, 25, 55-71.	3.5	510
10	Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe. Nano Letters, 2006, 6, 1-6.	9.1	477
11	Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. Chemical Reviews, 2015, 115, 10907-10937.	47.7	401
12	Nanotheranostics and Image-Guided Drug Delivery: Current Concepts and Future Directions. Molecular Pharmaceutics, 2010, 7, 1899-1912.	4.6	344
13	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 2013, 65, 1284-1298.	13.7	338
14	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. Journal of Controlled Release, 2003, 91, 115-122.	9.9	298
15	Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. Journal of Controlled Release, 2005, 103, 341-353.	9.9	286
16	Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis and Rheumatism, 2003, 48, 2059-2066.	6.7	281
17	Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Current Opinion in Biotechnology, 2013, 24, 1159-1166.	6.6	279
18	Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. International Journal of Pharmaceutics, 2011, 416, 433-442.	5.2	278

#	Article	IF	CITATIONS
19	Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines. Nano Letters, 2014, 14, 972-981.	9.1	272
20	The battle of "nano―paclitaxel. Advanced Drug Delivery Reviews, 2017, 122, 20-30.	13.7	270
21	MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB Journal, 2005, 19, 2008-2010.	0.5	247
22	Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials, 2010, 31, 7797-7804.	11.4	241
23	The role of liposomes in clinical nanomedicine development. What now? Now what?. Journal of Controlled Release, 2020, 318, 256-263.	9.9	226
24	Multidrug resistance: Physiological principles and nanomedical solutions. Advanced Drug Delivery Reviews, 2013, 65, 1852-1865.	13.7	220
25	Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials, 2009, 30, 3466-3475.	11.4	219
26	A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular Targets. Bioconjugate Chemistry, 2004, 15, 799-806.	3.6	216
27	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. Journal of Controlled Release, 2018, 277, 1-13.	9.9	214
28	Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. International Journal of Pharmaceutics, 2016, 499, 358-367.	5.2	207
29	Synovial macrophage depletion with clodronateâ€containing liposomes in rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 1951-1959.	6.7	198
30	Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Advanced Drug Delivery Reviews, 2017, 119, 44-60.	13.7	194
31	Drug targeting by longâ€circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.	7.6	190
32	Superparamagnetic Iron Oxide Nanoparticles Encapsulated in Biodegradable Thermosensitive Polymeric Micelles: Toward a Targeted Nanomedicine Suitable for Image-Guided Drug Delivery. Langmuir, 2009, 25, 2060-2067.	3.5	187
33	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel <i>via</i> ΖΠStacking Stabilized Polymeric Micelles. ACS Nano, 2015, 9, 3740-3752.	14.6	185
34	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano, 2011, 5, 4422-4433.	14.6	183
35	Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine, 2004, 22, 1903-1913.	3.8	181
36	Targeting tumor antigens to dendritic cells using particulate carriers. Journal of Controlled Release, 2012, 161, 25-37.	9.9	174

#	Article	IF	CITATIONS
37	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	10.3	173
38	Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. Journal of Controlled Release, 2011, 150, 30-36.	9.9	171
39	A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice. Blood, 2003, 102, 2522-2531.	1.4	168
40	Personalized Nanomedicine. Clinical Cancer Research, 2012, 18, 4889-4894.	7.0	166
41	Liposomes: quo vadis?. Pharmaceutical Science & Technology Today, 1998, 1, 19-31.	0.7	164
42	Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1198-1208.	6.7	164
43	Immunoliposomes for the targeted delivery of antitumor drugs. Advanced Drug Delivery Reviews, 1999, 40, 103-127.	13.7	163
44	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release, 2012, 160, 88-95.	9.9	158
45	Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins. Journal of Biological Chemistry, 2002, 277, 27135-27143.	3.4	157
46	Cancer nanomedicine: is targeting our target?. Nature Reviews Materials, 2016, 1, .	48.7	154
47	Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1193-1204.	4.3	146
48	Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative. Scientific Reports, 2017, 7, 14322.	3.3	146
49	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. International Journal of Pharmaceutics, 2007, 331, 211-214.	5.2	145
50	Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Advanced Drug Delivery Reviews, 2018, 129, 37-53.	13.7	145
51	Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis. Molecular Pharmaceutics, 2010, 7, 2020-2029.	4.6	144
52	Annexin A5-Conjugated Quantum Dots with a Paramagnetic Lipidic Coating for the Multimodal Detection of Apoptotic Cells. Bioconjugate Chemistry, 2006, 17, 865-868.	3.6	141
53	A Novel Family ofl-Amino Acid-Based Biodegradable Polymerâ^'Lipid Conjugates for the Development of Long-Circulating Liposomes with Effective Drug-Targeting Capacity. Bioconjugate Chemistry, 2003, 14, 1156-1164.	3.6	140
54	Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots. Angiogenesis, 2009, 12, 17-24.	7.2	139

#	Article	IF	CITATIONS
55	Dexamethasone nanomedicines for COVID-19. Nature Nanotechnology, 2020, 15, 622-624.	31.5	138
56	Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. Journal of Antimicrobial Chemotherapy, 2001, 48, 333-344.	3.0	135
57	Targeting the Stat6 pathway in tumorâ€associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB Journal, 2018, 32, 969-978.	0.5	134
58	Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis and Rheumatism, 2005, 52, 1314-1318.	6.7	133
59	Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. Journal of Controlled Release, 2012, 163, 75-81.	9.9	133
60	Nanomedicines for Inflammatory Arthritis: Head-to-Head Comparison of Glucocorticoid-Containing Polymers, Micelles, and Liposomes. ACS Nano, 2014, 8, 458-466.	14.6	133
61	Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1039-1046.	3.3	127
62	Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today, 2010, 5, 197-212.	11.9	126
63	Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. Journal of Controlled Release, 2005, 110, 103-118.	9.9	125
64	Physicoâ€Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumorâ€Targeted Drug Delivery. Macromolecular Bioscience, 2017, 17, 1600160.	4.1	125
65	Nanomedicines as Cancer Therapeutics: Current Status. Current Cancer Drug Targets, 2013, 13, 362-378.	1.6	123
66	Theranostic USPIOâ€Loaded Microbubbles for Mediating and Monitoring Bloodâ€Brain Barrier Permeation. Advanced Functional Materials, 2015, 25, 36-43.	14.9	123
67	Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discovery Today: Technologies, 2016, 20, 41-48.	4.0	120
68	Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration. Journal of Controlled Release, 2016, 244, 257-268.	9.9	119
69	Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. Journal of Controlled Release, 2016, 231, 77-85.	9.9	119
70	Annexin A5-Functionalized Bimodal Lipid-Based Contrast Agents for the Detection of Apoptosis. Bioconjugate Chemistry, 2006, 17, 741-749.	3.6	117
71	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of Controlled Release, 2010, 145, 165-175.	9.9	117
72	SiRNA delivery with functionalized carbon nanotubes. International Journal of Pharmaceutics, 2011, 416, 419-425.	5.2	117

#	Article	IF	CITATIONS
73	Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials, 2015, 37, 367-382.	11.4	115
74	Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials, 2013, 34, 1255-1260.	11.4	111
75	In Vivo Methods to Study Uptake of Nanoparticles into the Brain. Pharmaceutical Research, 2011, 28, 456-471.	3.5	110
76	Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. Journal of Controlled Release, 2007, 117, 333-341.	9.9	109
77	MicroRNA Targeting to Modulate Tumor Microenvironment. Frontiers in Oncology, 2016, 6, 3.	2.8	108
78	Liposomal Drug Formulations in the Treatment of Rheumatoid Arthritis. Molecular Pharmaceutics, 2011, 8, 1002-1015.	4.6	107
79	Atherosclerotic Plaque Targeting Mechanism of Long-Circulating Nanoparticles Established by Multimodal Imaging. ACS Nano, 2015, 9, 1837-1847.	14.6	105
80	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget, 2014, 5, 6687-6700.	1.8	105
81	In vivo nanotoxicity testing using the zebrafish embryo assay. Journal of Materials Chemistry B, 2013, 1, 3918.	5.8	104
82	Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2015, 23, 103-131.	11.6	104
83	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. Journal of Controlled Release, 2017, 247, 127-133.	9.9	104
84	Effect of Intratumoral Injection on the Biodistribution, the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems. Neoplasia, 2006, 8, 788-795.	5.3	103
85	Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 227-236.	2.6	102
86	Liposomes in the treatment of inflammatory disorders. Expert Opinion on Drug Delivery, 2005, 2, 465-476.	5.0	102
87	Glucocorticoid‣oaded Coreâ€Cross‣inked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis. Angewandte Chemie - International Edition, 2012, 51, 7254-7258.	13.8	102
88	Noninvasive Optical Imaging of Nanomedicine Biodistribution. ACS Nano, 2013, 7, 252-262.	14.6	102
89	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1419, 325-334.	2.6	101
90	Nanotechnological approaches for the delivery of macromolecules. Journal of Controlled Release, 2003, 87, 81-88.	9.9	101

#	Article	IF	CITATIONS
91	OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1665, 48-56.	2.6	101
92	Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. International Journal of Pharmaceutics, 2007, 331, 167-175.	5.2	101
93	Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice. Neoplasia, 2005, 7, 118-127.	5.3	99
94	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6731-E6740.	7.1	95
95	Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. Journal of Controlled Release, 2011, 151, 183-192.	9.9	94
96	Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. Advanced Drug Delivery Reviews, 2021, 175, 113801.	13.7	92
97	Drug targeting systems for inflammatory disease: One for all, all for one. Journal of Controlled Release, 2012, 161, 225-234.	9.9	88
98	Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials, 2015, 53, 370-378.	11.4	88
99	Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. Journal of Controlled Release, 2018, 290, 1-10.	9.9	88
100	Effects of Physicochemical Characteristics of Poly(2-(dimethylamino)ethyl methacrylate)-Based Polyplexes on Cellular Association and Internalization. Journal of Drug Targeting, 2000, 8, 51-66.	4.4	87
101	Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anti-Cancer Drugs, 2011, 22, 223-233.	1.4	87
102	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1211-1217.	2.6	86
103	Sonochemotherapy: from bench to bedside. Frontiers in Pharmacology, 2015, 6, 138.	3.5	84
104	Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). , 1997, 14, 1479-1484.		83
105	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	9.9	83
106	Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. Journal of Controlled Release, 2014, 182, 83-89.	9.9	83
107	Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal, 2007, 21, 378-383.	0.5	82
108	Poly(amino acid)s: Promising enzymatically degradable stealth coatings for liposomes. International Journal of Pharmaceutics, 2007, 331, 186-189.	5.2	82

#	Article	IF	CITATIONS
109	Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue. Neoplasia, 2008, 10, 108-117.	5.3	82
110	Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochemical and Biophysical Research Communications, 2015, 468, 490-497.	2.1	81
111	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Science Advances, 2019, 5, eaax2770.	10.3	81
112	Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1138, 318-326.	3.8	80
113	Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. Journal of Controlled Release, 2014, 195, 2-10.	9.9	79
114	Nanomedicine Strategies to Target Tumor-Associated Macrophages. International Journal of Molecular Sciences, 2017, 18, 979.	4.1	79
115	Gold Nanocrystal Labeling Allows Low-Density Lipoprotein Imaging from the Subcellular to Macroscopic Level. ACS Nano, 2013, 7, 9761-9770.	14.6	77
116	Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation. Expert Opinion on Drug Delivery, 2018, 15, 1249-1261.	5.0	76
117	Liposomes for scintigraphic detection of infection and inflammation. Advanced Drug Delivery Reviews, 1999, 37, 225-235.	13.7	75
118	Liposomes: From the Bench to the Bed. Journal of Liposome Research, 2003, 13, 33-36.	3.3	75
119	Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. Journal of Controlled Release, 2014, 190, 624-636.	9.9	75
120	Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. Journal of Controlled Release, 2020, 319, 407-415.	9.9	74
121	Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 737-743.	2.6	73
122	Inhibition of canonical WNT signaling pathway by β-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 804-818.	3.8	73
123	MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget, 2016, 7, 16396-16408.	1.8	72
124	Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharmaceutical Research, 1992, 09, 260-265.	3.5	70
125	The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific Reports, 2016, 5, 18272.	3.3	70
126	Nanopolymersomes with an Ultrahigh Iodine Content for Highâ€Performance Xâ€Ray Computed Tomography Imaging In Vivo. Advanced Materials, 2017, 29, 1603997.	21.0	70

#	Article	IF	CITATIONS
127	In vivo tumor transfection mediated by polyplexes based on biodegradable poly(DMAEA)-phosphazene. Journal of Controlled Release, 2005, 109, 275-287.	9.9	69

Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70

129	Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. Journal of Controlled Release, 2015, 203, 67-76.	9.9	68
130	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release, 2010, 141, 234-240.	9.9	67
131	Temperature-Sensitive Poly(<i>N</i> -(2-hydroxypropyl)methacrylamide mono/dilactate)-Coated Liposomes for Triggered Contents Release. Bioconjugate Chemistry, 2007, 18, 2131-2136.	3.6	66
132	Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. Journal of Controlled Release, 2022, 341, 475-486.	9.9	66
133	In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharmaceutical Research, 2003, 20, 64-72.	3.5	65
134	Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. Journal of Controlled Release, 2012, 164, 87-94.	9.9	65
135	Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. Journal of Controlled Release, 2006, 113, 1-8.	9.9	64
136	Hyperthermiaâ€Induced Drug Delivery from Thermosensitive Liposomes Encapsulated in an Injectable Hydrogel for Local Chemotherapy. Advanced Healthcare Materials, 2014, 3, 854-859.	7.6	64
137	MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. Journal of Controlled Release, 2015, 216, 37-46.	9.9	64
138	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature Reviews Cardiology, 2011, 8, 338-347.	13.7	63
139	Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. Nanomedicine, 2016, 11, 2889-2902.	3.3	63
140	Targeting distinct myeloid cell populations inÂvivo using polymers, liposomes and microbubbles. Biomaterials, 2017, 114, 106-120.	11.4	63
141	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovascular Research, 2018, 114, 1714-1727.	3.8	63
142	Targeted Delivery of siRNA. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-9.	3.0	62
143	Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier. Pharmaceutical Research, 2010, 27, 673-682.	3.5	62
144	Gene Silencing Activity of siRNA Polyplexes Based on Thiolated <i>N</i> , <i>N</i> , <i>N</i> -Trimethylated Chitosan. Bioconjugate Chemistry, 2010, 21, 2339-2346.	3.6	62

#	Article	IF	CITATIONS
145	Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. Journal of Controlled Release, 2007, 117, 186-195.	9.9	61
146	Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. Blood, 2008, 111, 4542-4550.	1.4	61
147	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Experimental and Molecular Medicine, 2017, 49, e396-e396.	7.7	61
148	In Vivo Applications of PEG Liposomes: Unexpected Observations. Critical Reviews in Therapeutic Drug Carrier Systems, 2001, 18, 16.	2.2	61
149	Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. Journal of Drug Targeting, 2000, 8, 225-233.	4.4	60
150	Comparative transfection studies of human ovarian carcinoma cellsin vitro,ex vivo andin vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. Journal of Gene Medicine, 1999, 1, 156-165.	2.8	59
151	Biodegradable Poly(2-Dimethylamino Ethylamino)Phosphazene for In Vivo Gene Delivery to Tumor Cells. Effect of Polymer Molecular Weight. Pharmaceutical Research, 2007, 24, 1572-1580.	3.5	59
152	Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. International Journal of Pharmaceutics, 2005, 304, 185-192.	5.2	58
153	Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discovery Today, 2003, 8, 482-483.	6.4	56
154	Evidence for a new mechanism behind HIFU-triggered release from liposomes. Journal of Controlled Release, 2013, 168, 327-333.	9.9	56
155	Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget, 2016, 7, 3341-3356.	1.8	56
156	Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes. International Journal of Pharmaceutics, 2012, 438, 209-216.	5.2	55
157	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. Journal of Controlled Release, 2012, 161, 772-780.	9.9	55
158	Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. Cancer Letters, 2018, 420, 247-258.	7.2	55
159	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opinion on Biological Therapy, 2006, 6, 605-617.	3.1	54
160	Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. Journal of Steroid Biochemistry and Molecular Biology, 2008, 111, 101-110.	2.5	54
161	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. Human Gene Therapy, 2009, 20, 181-189.	2.7	54
162	Selective tumor antigen vaccine delivery to human CD169 ⁺ antigen-presenting cells using ganglioside-liposomes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27528-27539.	7.1	54

#	Article	IF	CITATIONS
163	Immunoliposomes in Vivo. ImmunoMethods, 1994, 4, 259-272.	0.8	53
164	Overcoming cellular multidrug resistance using classical nanomedicine formulations. European Journal of Pharmaceutical Sciences, 2012, 45, 421-428.	4.0	53
165	Triggered Release of Doxorubicin from Temperature-Sensitive Poly(<i>N</i> -(2-hydroxypropyl)-methacrylamide mono/dilactate) Grafted Liposomes. Biomacromolecules, 2014, 15, 1002-1009.	5.4	52
166	Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo. Journal of Controlled Release, 2018, 290, 141-149.	9.9	52
167	Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses. PLoS ONE, 2011, 6, e28917.	2.5	52
168	Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1421, 329-339.	2.6	51
169	Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer. Journal of Liposome Research, 2006, 16, 185-194.	3.3	51
170	Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. Journal of Controlled Release, 2011, 151, 10-17.	9.9	51
171	Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. International Journal of Pharmaceutics, 2011, 416, 471-477.	5.2	51
172	MRI of ICAM-1 Upregulation After Stroke: the Importance of Choosing the Appropriate Target-Specific Particulate Contrast Agent. Molecular Imaging and Biology, 2013, 15, 411-422.	2.6	50
173	Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. Biomaterials, 2018, 178, 481-495.	11.4	50
174	Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 161-171.	1.7	49
175	Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. European Journal of Pharmaceutical Sciences, 2003, 20, 419-427.	4.0	49
176	Lanthanide-Loaded Liposomes for Multimodality Imaging and Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 520-527.	1.0	49
177	Complement activation by PEGylated liposomes containing prednisolone. European Journal of Pharmaceutical Sciences, 2013, 49, 265-271.	4.0	49
178	Duration of ultrasound-mediated enhanced plasma membrane permeability. International Journal of Pharmaceutics, 2015, 482, 92-98.	5.2	49
179	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocrine-Related Cancer, 2016, 23, 35-45.	3.1	49
180	Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treatment Reviews, 2014, 40, 578-584.	7.7	48

#	Article	IF	CITATIONS
181	Microscopic localization of PEG-liposomes in a rat model of focal infection. Journal of Controlled Release, 2001, 75, 347-355.	9.9	47
182	Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. Journal of Controlled Release, 2010, 148, 303-310.	9.9	47
183	Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity. Pharmaceutical Research, 2011, 28, 1013-1022.	3.5	47
184	Applying nanomedicine in maladaptive inflammation and angiogenesis. Advanced Drug Delivery Reviews, 2017, 119, 143-158.	13.7	46
185	The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochimica Et Biophysica Acta - Biomembranes, 1985, 818, 343-351.	2.6	45
186	Polyplexes based on cationic polymers with strong nucleic acid binding properties. European Journal of Pharmaceutical Sciences, 2012, 45, 459-466.	4.0	45
187	Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes. Journal of Controlled Release, 2014, 187, 158-166.	9.9	45
188	Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Trends in Pharmacological Sciences, 2016, 37, 451-462.	8.7	45
189	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharmaceutical Research, 2000, 17, 600-606.	3.5	44
190	Effect of Liposome Characteristics and Dose on the Pharmacokinetics of Liposomes Coated with Poly(amino acid)s. Pharmaceutical Research, 2007, 24, 2394-2401.	3.5	44
191	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. Journal of Controlled Release, 2017, 262, 47-57.	9.9	44
192	Liposomal Targeting of Prednisolone Phosphate to Synovial Lining Macrophages during Experimental Arthritis Inhibits M1 Activation but Does Not Favor M2 Differentiation. PLoS ONE, 2013, 8, e54016.	2.5	43
193	Liposomes and biotherapeutics. Biotherapy (Dordrecht, Netherlands), 1991, 3, 25-42.	0.7	41
194	Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1468, 253-261.	2.6	41
195	Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections. Methods in Enzymology, 2005, 391, 228-260.	1.0	41
196	Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. Journal of Controlled Release, 2011, 152, 363-369.	9.9	41
197	Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo. Prostate, 2015, 75, 815-824.	2.3	41
198	Radionuclide imaging of liposomal drug delivery. Expert Opinion on Drug Delivery, 2016, 13, 1231-1242.	5.0	41

#	Article	IF	CITATIONS
199	Liposomes for Intravenous Drug Targeting: Design and Applications. Mini-Reviews in Medicinal Chemistry, 2002, 2, 319-329.	2.4	41
200	Immunoliposomes in vivo: state of the art. Advanced Drug Delivery Reviews, 1988, 1, 249-266.	13.7	40
201	Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. International Journal of Nanomedicine, 2016, Volume 11, 5027-5040.	6.7	40
202	Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomaterialia, 2019, 92, 196-204.	8.3	40
203	Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. Cancer Gene Therapy, 2001, 8, 405-413.	4.6	39
204	Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharmaceutical Research, 2003, 20, 423-428.	3.5	39
205	Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Scientific Reports, 2017, 7, 44545.	3.3	39
206	Gene silencing activity of siRNA polyplexes based on biodegradable polymers. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 450-457.	4.3	38
207	Image-guided drug delivery: preclinical applications and clinical translation. Expert Opinion on Drug Delivery, 2015, 12, 1203-1207.	5.0	38
208	Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles. Journal of Controlled Release, 2016, 238, 157-165.	9.9	38
209	Transporting silence: Design of carriers for siRNA to angiogenic endothelium. Journal of Controlled Release, 2005, 109, 5-14.	9.9	37
210	Cytosolic Delivery of Liposomally Targeted Proteins Induced by Photochemical Internalization. Pharmaceutical Research, 2007, 24, 2040-2047.	3.5	37
211	Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. Journal of Controlled Release, 2008, 127, 131-136.	9.9	37
212	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1133-1140.	3.3	37
213	Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications. Journal of Controlled Release, 2016, 244, 314-325.	9.9	37
214	Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. Journal of Controlled Release, 2018, 288, 227-238.	9.9	37
215	The hepatic lipidome: From basic science to clinical translation. Advanced Drug Delivery Reviews, 2020, 159, 180-197.	13.7	37
216	Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharmaceutical Research, 1996, 13, 604-610.	3.5	36

#	Article	IF	CITATIONS
217	Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting. Current Pharmaceutical Biotechnology, 2012, 13, 609-622.	1.6	36
218	Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression. Pharmaceutical Research, 2012, 29, 669-682.	3.5	36
219	Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information. Journal of Controlled Release, 2018, 270, 268-274.	9.9	36
220	Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. Journal of Controlled Release, 2019, 309, 333-338.	9.9	36
221	Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo. Journal of Controlled Release, 2021, 337, 521-529.	9.9	36
222	Enhanced engraftment of human cells in RAG2/γc double-knockout mice after treatment with CL2MDP liposomes. Experimental Hematology, 2004, 32, 1118-1125.	0.4	35
223	Enzymatic Degradation of Liposome-Grafted Poly(hydroxyethyl l-glutamine). Bioconjugate Chemistry, 2005, 16, 767-774.	3.6	35
224	In situ Delivery of Antigen to DC-SIGN + CD14 + Dermal Dendritic Cells Results in Enhanced CD8 + T-Cell Responses. Journal of Investigative Dermatology, 2015, 135, 2228-2236.	0.7	35
225	Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs) ameliorate hepatic stellate cells activation in vitro and acute liver injury in vivo. Journal of Controlled Release, 2020, 328, 640-652.	9.9	35
226	MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. European Journal of Pharmaceutical Sciences, 2012, 45, 436-441.	4.0	34
227	Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor. Theranostics, 2019, 9, 8061-8072.	10.0	34
228	Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget, 2014, 5, 3159-3167.	1.8	34
229	Lymphatic Uptake and Biodistribution of Liposomes after Subcutaneous Injection I. Influence of the Anatomical Site of Injection. Journal of Liposome Research, 1997, 7, 85-99.	3.3	33
230	Strategies for cytosolic delivery of liposomal macromolecules. International Journal of Pharmaceutics, 2005, 298, 305-309.	5.2	33
231	DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. International Journal of Pharmaceutics, 2011, 416, 426-432.	5.2	33
232	Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphateâ€containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. Journal of Neurochemistry, 2012, 123, 65-74.	3.9	33
233	Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Scientific Reports, 2018, 8, 6604.	3.3	33
234	Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica, 2020, 41, 954-958.	6.1	33

#	Article	IF	CITATIONS
235	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. Frontiers in Immunology, 2021, 12, 697840.	4.8	33
236	Sterically stabilized amphotericin B-liposomes: toxicity and biodistribution in mice. Journal of Controlled Release, 1995, 37, 123-129.	9.9	32
237	Design of immunoliposomes directed against human ovarian carcinoma. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1235, 126-139.	2.6	32
238	Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil. Pharmaceutical Research, 2008, 25, 1948-1955.	3.5	32
239	Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells. International Journal of Pharmaceutics, 2008, 364, 258-264.	5.2	32
240	A method for quantifying cellular uptake of fluorescently labeled siRNA. Journal of Controlled Release, 2010, 148, 106-109.	9.9	32
241	Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics. European Journal of Pharmaceutical Sciences, 2012, 45, 429-435.	4.0	32
242	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti–Fibroblast Activation Protein Antibody. Journal of Nuclear Medicine, 2017, 58, 151-155.	5.0	32
243	Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 704-710.	2.5	31
244	Superoxide Dismutase Enzymosomes: Carrier Capacity Optimization, in Vivo Behaviour and Therapeutic Activity. Pharmaceutical Research, 2015, 32, 91-102.	3.5	31
245	Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells. Nanomedicine, 2017, 12, 1369-1384.	3.3	31
246	E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells. International Journal of Pharmaceutics, 2018, 548, 759-770.	5.2	31
247	Î electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. Biomaterials, 2021, 266, 120432.	11.4	31
248	Novel developments in liposomal delivery of peptides and proteins. Journal of Controlled Release, 1995, 36, 19-24.	9.9	30
249	Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin. Antimicrobial Agents and Chemotherapy, 2001, 45, 464-470.	3.2	30
250	CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Research, 2005, 7, R604.	2.0	30
251	A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. Journal of Controlled Release, 2015, 205, 98-108.	9.9	30
252	Influence of cholesterol inclusion on the doxorubicin release characteristics of lysolipid-based thermosensitive liposomes. International Journal of Pharmaceutics, 2018, 548, 778-782.	5.2	30

#	Article	IF	CITATIONS
253	FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. Nanotheranostics, 2020, 4, 26-39.	5.2	30
254	Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. Journal of Controlled Release, 2020, 328, 805-816.	9.9	30
255	Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation. Theranostics, 2020, 10, 1948-1959.	10.0	30
256	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	4.2	30
257	Targeting liposomes to tumor endothelial cells for neutron capture therapy. Applied Radiation and Isotopes, 2004, 61, 963-967.	1.5	29
258	Reprint of "Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". Journal of Controlled Release, 2011, 153, 93-102.	9.9	29
259	Trends in polymeric delivery of nucleic acids to tumors. Journal of Controlled Release, 2013, 170, 209-218.	9.9	29
260	Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention. International Journal of Pharmaceutics, 2016, 506, 407-413.	5.2	29
261	Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors. Journal of Controlled Release, 2018, 282, 25-34.	9.9	29
262	Nanomedicine at the crossroads – A quick guide for IVIVC. Advanced Drug Delivery Reviews, 2021, 179, 113829.	13.7	29
263	Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 106-118.	3.3	28
264	Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. Experimental Hematology, 2010, 38, 282-291.	0.4	27
265	Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonide. International Journal of Pharmaceutics, 2011, 416, 493-498.	5.2	27
266	Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding. European Journal of Pharmaceutical Sciences, 2012, 45, 330-335.	4.0	27
267	Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells. Clinical Cancer Research, 2013, 19, 1467-1475.	7.0	27
268	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. Journal of Controlled Release, 2019, 296, 232-240.	9.9	27
269	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity Implications in experimental and clinical oncology. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 227-229.	2.4	26
270	Synthetic vehicles for DNA vaccination. Journal of Drug Targeting, 2010, 18, 1-14.	4.4	26

#	Article	IF	CITATIONS
271	Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging. Methods in Enzymology, 2012, 508, 211-228.	1.0	26
272	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	4.6	26
273	TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLS. Journal of Liposome Research, 2002, 12, 57-65.	3.3	25
274	Plasmid CpG Depletion Improves Degree and Duration of Tumor Gene Expression After Intravenous Administration of Polyplexes. Pharmaceutical Research, 2008, 25, 1654-1662.	3.5	25
275	Alginate Microspheres Containing Temperature Sensitive Liposomes (TSL) for MR-Guided Embolization and Triggered Release of Doxorubicin. PLoS ONE, 2015, 10, e0141626.	2.5	25
276	In situ Delivery of Tumor Antigen– and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells. Journal of Investigative Dermatology, 2015, 135, 2697-2704.	0.7	25
277	Locoregional cancer therapy using polymer-based drug depots. Drug Discovery Today, 2016, 21, 640-647.	6.4	25
278	Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Letters, 1996, 399, 232-236.	2.8	24
279	Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes. International Journal of Pharmaceutics, 2008, 355, 108-113.	5.2	24
280	Eradication of Medullary Multiple Myeloma by CD4+ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen. Clinical Cancer Research, 2010, 16, 5481-5488.	7.0	24
281	A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. International Journal of Nanomedicine, 2011, 6, 2697.	6.7	23
282	Comparison of three remote radiolabelling methods for long-circulating liposomes. Journal of Controlled Release, 2015, 220, 239-244.	9.9	23
283	[18]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. Journal of Controlled Release, 2015, 209, 20-26.	9.9	23
284	Targeting influenza virosomes to ovarian carcinoma cells. FEBS Letters, 2001, 509, 71-76.	2.8	22
285	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 2012, 7, 417.	6.7	22
286	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. Rheumatology, 2018, 57, 737-747.	1.9	22
287	Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo. Biomaterials, 2019, 206, 49-60.	11.4	22
288	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹ Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	3.6	22

#	Article	IF	CITATIONS
289	Interaction of Recombinant Interleukin-2 with Liposomal Bilayers. Journal of Pharmaceutical Sciences, 1998, 87, 707-714.	3.3	21
290	Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release, 2008, 132, 200-207.	9.9	21
291	Utility of Targeted Glucocorticoids in Cancer Therapy. Journal of Liposome Research, 2008, 18, 47-57.	3.3	21
292	Biodegradable, Cationic Methacrylamide-Based Polymers for Gene Delivery to Ovarian Cancer Cells in Mice. Molecular Pharmaceutics, 2008, 5, 349-357.	4.6	21
293	Cationic polymeric gene delivery of β-glucuronidase for doxorubicin prodrug therapy. Journal of Gene Medicine, 1999, 1, 407-414.	2.8	20
294	Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines. Journal of Controlled Release, 2012, 160, 232-238.	9.9	20
295	Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits. European Journal of Nanomedicine, 2013, 5, .	0.6	20
296	Alginate microgels loaded with temperature sensitive liposomes for magnetic resonance imageable drug release and microgel visualization. European Polymer Journal, 2015, 72, 620-631.	5.4	20
297	Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro. PLoS ONE, 2016, 11, e0155325.	2.5	20
298	Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines, 2021, 9, 56.	4.4	20
299	ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opinion on Drug Delivery, 2006, 3, 445-454.	5.0	19
300	Tumor vasculature as target for therapeutic intervention. Expert Opinion on Investigational Drugs, 2010, 19, 1321-1338.	4.1	19
301	Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Letters, 1997, 409, 91-95.	2.8	18
302	HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine, 2010, 5, 1501-1523.	3.3	18
303	Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate. Bioconjugate Chemistry, 2011, 22, 540-545.	3.6	18
304	Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Advanced Drug Delivery Reviews, 1997, 24, 225-231.	13.7	17
305	LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE. Journal of Liposome Research, 2002, 12, 129-135.	3.3	17
306	Radiolabeling of Liposomes for Scintigraphic Imaging. Methods in Enzymology, 2003, 373, 234-248.	1.0	17

#	Article	IF	CITATIONS
307	New Insights into the HIFU-Triggered Release from Polymeric Micelles. Langmuir, 2013, 29, 9483-9490.	3.5	17
308	PEC-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. Polymer Chemistry, 2014, 5, 1674-1681.	3.9	17
309	Fluorophore labeling of core-crosslinked polymeric micelles for multimodal <i>in vivo</i> and <i>ex vivo</i> optical imaging. Nanomedicine, 2015, 10, 1111-1125.	3.3	17
310	Shelf-Life Evaluation and Lyophilization of PBCA-Based Polymeric Microbubbles. Pharmaceutics, 2019, 11, 433.	4.5	17
311	Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. PLoS ONE, 2020, 15, e0235657.	2.5	17
312	Lyophilization stabilizes clinicalâ€stage coreâ€crosslinked polymeric micelles to overcome cold chain supply challenges. Biotechnology Journal, 2021, 16, e2000212.	3.5	17
313	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Advanced Drug Delivery Reviews, 2021, 175, 113831.	13.7	17
314	TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis <i>in vivo</i> . FASEB Journal, 2019, 33, 9466-9475.	0.5	16
315	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. Fundamental Biomedical Technologies, 2016, , 163-200.	0.2	16
316	Role of spleen tyrosine kinase in liver diseases. World Journal of Gastroenterology, 2020, 26, 1005-1019.	3.3	16
317	Administration of prednisolone phosphate?liposomes reduces wound contraction in a rat partial-thickness wound model. Wound Repair and Regeneration, 2006, 14, 602-607.	3.0	15
318	Therapeutic Nanomedicine: Cross linked micelles with transiently linked drugs – a versatile drug delivery system. European Journal of Nanomedicine, 2010, 3, 19-24.	0.6	15
319	Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. Pharmaceutics, 2020, 12, 1138.	4.5	15
320	Alveolar macrophages have a dual role in a rat model for trimellitic anhydride-induced occupational asthma. Toxicology and Applied Pharmacology, 2006, 211, 20-29.	2.8	14
321	Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model. Journal of Controlled Release, 2016, 243, 243-249.	9.9	14
322	Lipogels responsive to near-infrared light for the triggered release of therapeutic agents. Acta Biomaterialia, 2017, 61, 54-65.	8.3	14
323	Therapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
324	1H NMR Spectroscopy as a Tool for Determining the Composition of Poly(hydroxyethyl-l-asparagine)-Coated Liposomes. Bioconjugate Chemistry, 2006, 17, 860-864.	3.6	13

#	Article	IF	CITATIONS
325	Alveolar macrophages suppress non-specific inflammation caused by inhalation challenge with trimellitic anhydride conjugated to albumin. Archives of Toxicology, 2006, 80, 561-571.	4.2	13
326	Targeted Delivery of Anti-Inflammatory Agents to Tumors. Current Pharmaceutical Design, 2009, 15, 1825-1843.	1.9	13
327	Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. Angiogenesis, 2011, 14, 143-153.	7.2	13
328	Nanoclusters of Iron Oxide: Effect of Core Composition on Structure, Biocompatibility, and Cell Labeling Efficacy. Bioconjugate Chemistry, 2012, 23, 941-950.	3.6	13
329	Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. Future Microbiology, 2018, 13, 1683-1692.	2.0	13
330	Development and characterization of liposomal formulation of bortezomib. International Journal of Pharmaceutics: X, 2019, 1, 100011.	1.6	13
331	High-resolution 3D visualization of nanomedicine distribution in tumors. Theranostics, 2020, 10, 880-897.	10.0	13
332	Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro. Journal of Liposome Research, 1989, 1, 195-210.	3.3	12
333	Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. Advanced Drug Delivery Reviews, 1995, 17, 21-30.	13.7	12
334	Synthetic delivery systems for intravenous administration of nucleic acids. Nanomedicine, 2007, 2, 169-181.	3.3	12
335	Nanomedicine formulations for combination therapies. Nano Reviews, 2010, 1, 5705.	3.7	12
336	Macromolecular nanotheranostics for multimodal anticancer therapy. Nanoscale, 2011, 3, 4022.	5.6	12
337	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discovery Today, 2021, 26, 1482-1489.	6.4	12
338	Development of a routine analysis method for liposome encapsulated recombinant interleukin-2. Biomedical Applications, 1998, 716, 285-291.	1.7	11
339	Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. International Journal of Pharmaceutics, 2001, 214, 103-105.	5.2	11
340	siRNA-mediated inhibition of angiogenesis. Expert Opinion on Biological Therapy, 2005, 5, 359-368.	3.1	11
341	Liposomal Targeting of Angiogenic Vasculature. Current Drug Delivery, 2005, 2, 363-368.	1.6	11
342	Quantitative Assessment of Human T Lymphocytes in RAG2â^'/â^'γcâ^'/â^' Mice: The Impact of Ex Vivo Manipulation on In Vivo Functionality. Experimental Hematology, 2007, 35, 117-127.	0.4	11

#	Article	IF	CITATIONS
343	Liposomal doxorubicin: the good, the bad and the not-so-ugly. Journal of Drug Targeting, 2016, 24, 765-767.	4.4	11
344	Systematic evaluation of design features enables efficient selection of Î electron-stabilized polymeric micelles. International Journal of Pharmaceutics, 2020, 584, 119409.	5.2	11
345	Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. FEBS Letters, 1996, 395, 245-250.	2.8	10
346	Liposomes: The Science and the Regulatory Landscape. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 77-106.	0.6	10
347	A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. British Journal of Ophthalmology, 2021, 105, 1617-1622.	3.9	10
348	Ultrasound and Microbubbles for the Treatment of Ocular Diseases: From Preclinical Research towards Clinical Application. Pharmaceutics, 2021, 13, 1782.	4.5	10
349	Site-specific pharmaco-laser therapy: A novel treatment modality for refractory port wine stains. Journal of Clinical and Translational Research, 2019, 5, 1-24.	0.3	10
350	Lyophilization of TC-99m-Hynic Labeled Peg-Liposomes. Journal of Liposome Research, 2000, 10, 117-129.	3.3	9
351	Targeting cellular and microenvironmental multidrug resistance. Expert Opinion on Drug Delivery, 2016, 13, 1199-1202.	5.0	9
352	Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide) Tj ETQq0 0 0 rgBT /Overlock Pharmaceutics, 2018, 550, 190-199.	10 Tf 50 5	387 Td (monc 9
353	Scale-Up of the Manufacturing Process To Produce Docetaxel-Loaded mPEG- <i>b</i> -p(HPMA-Bz) Block Copolymer Micelles for Pharmaceutical Applications. Organic Process Research and Development, 2019, 23, 2707-2715.	2.7	9
354	Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo. International Journal of Pharmaceutics, 2020, 585, 119535.	5.2	9
355	Lyophilization Preserves the Intrinsic Cardioprotective Activity of Bioinspired Cell-Derived Nanovesicles. Pharmaceutics, 2021, 13, 1052.	4.5	9
356	Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes. Journal of Liposome Research, 2000, 10, 513-521.	3.3	8
357	Anginex lipoplexes for delivery of anti-angiogenic siRNA. International Journal of Pharmaceutics, 2014, 472, 175-184.	5.2	8
358	Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Vascular Pharmacology, 2016, 82, 51-59.	2.1	8
359	LIPOSOME-ENABLED SYNERGISTIC INTERACTION OF ANTIMICROBIAL AGENTS. Journal of Liposome Research, 2002, 12, 121-127.	3.3	7
360	Liposomes targeting tumour stromal cells. Molecular Membrane Biology, 2010, 27, 328-340.	2.0	7

#	Article	IF	CITATIONS
361	A novel approach to identify non-palpable breast lesions combining fluorescent liposomes and magnetic resonance-guided high intensity focused ultrasound-triggered release. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 458-464.	4.3	7
362	Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. PLoS ONE, 2015, 10, e0128466.	2.5	7
363	Development of a tumor tissue-mimicking model with endothelial cell layer and collagen gel for evaluating drug penetration. International Journal of Pharmaceutics, 2015, 482, 118-122.	5.2	7
364	High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. International Journal of Pharmaceutics, 2016, 514, 112-120.	5.2	7
365	Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles. International Journal of Pharmaceutics, 2018, 548, 793-802.	5.2	7
366	Environmental impact of switching from the synthetic glucocorticoid prednisolone to the natural alkaloid berberine. PLoS ONE, 2018, 13, e0199095.	2.5	7
367	Treatment Outcome Measurement Instruments for Port Wine Stains: A Systematic Review of Their Measurement Properties. Dermatology, 2021, 237, 416-432.	2.1	7
368	Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. Pharmaceutics, 2021, 13, 954.	4.5	7
369	TAT-Peptide Modified Liposomes: Preparation, Characterization, and Cellular Interaction. Methods in Molecular Biology, 2010, 605, 349-359.	0.9	7
370	Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses. Frontiers in Immunology, 2022, 13, 842241.	4.8	7
371	Targeting of peptide and protein drugs. European Journal of Pharmaceutical Sciences, 1994, 2, 17-18.	4.0	6
372	Tumor cell and tumor vasculature targeted liposomes for neutron capture therapy. Radiochimica Acta, 2005, 93, 589-593.	1.2	6
373	Targeting the retinal microcirculation to treat diabetic sight problems. Expert Opinion on Therapeutic Targets, 2007, 11, 1493-1502.	3.4	6
374	Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. International Journal of Pharmaceutics, 2011, 416, 448-452.	5.2	6
375	Application of cultured human regulatory TÂcells requires preclinical inÂvivo evaluation. Journal of Allergy and Clinical Immunology, 2012, 129, 852-855.e3.	2.9	6
376	Hybrid Materials: Theranostic USPIOâ€Loaded Microbubbles for Mediating and Monitoring Bloodâ€Brain Barrier Permeation (Adv. Funct. Mater. 1/2015). Advanced Functional Materials, 2015, 25, 2-2.	14.9	6
377	The Effect of Microbubble-Assisted Ultrasound on Molecular Permeability across Cell Barriers. Pharmaceutics, 2022, 14, 494.	4.5	6
378	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. HemaSphere, 2020, 4, e463.	2.7	5

#	Article	IF	CITATIONS
379	Liposomes for Local Sustained Drug Release. , 2000, , 137-180.		5
380	Photodynamic Therapy Targeting Macrophages Using IRDye700DX-Liposomes Decreases Experimental Arthritis Development. Pharmaceutics, 2021, 13, 1868.	4.5	5
381	The Design of a Pharmaceuttcally Acceptable Liposomal Formulation of Recombinant Interleukin-2 (Ril-2) for Locoregional Anticancer Immunotherapy. Journal of Liposome Research, 1999, 9, 313-329.	3.3	4
382	Hemocompatibility Assessment of two siRNA Nanocarrier Formulations. Pharmaceutical Research, 2014, 31, 3127-3135.	3.5	4
383	Absolute MR thermometry using nanocarriers. Contrast Media and Molecular Imaging, 2014, 9, 283-290.	0.8	4
384	Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses. Veterinary Journal, 2015, 206, 218-225.	1.7	4
385	Long-circulating liposomes for i.v. targeted delivery of glucocorticoids in arthritis. Cellular and Molecular Biology Letters, 2002, 7, 291-2.	7.0	4
386	Liposomal Delivery of Peptides and Proteins. Journal of Liposome Research, 1995, 5, 481-489.	3.3	3
387	Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. Drug Delivery and Translational Research, 2022, 12, 7-14.	5.8	3
388	Neovascular Age-Related Macular Degeneration. BioDrugs, 2011, 25, 171-189.	4.6	2
389	In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy. Pharmaceutics, 2020, 12, 591.	4.5	2
390	Radiolabeling of Liposomes for Scintigraphic Imaging. , 2006, , 169-185.		2
391	siRNA as a new drug: intellectual property. Expert Opinion on Therapeutic Patents, 2005, 15, 141-152.	5.0	1
392	Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine. European Journal of Nanomedicine, 2008, 1, .	0.6	1
393	Longâ€Circulating and Passively Tumorâ€Targeted Polymerâ€Drug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy. Advanced Engineering Materials, 2010, 12, B413.	3.5	1
394	The role of thromboxane A2 in complement activation-related pseudoallergy. European Journal of Nanomedicine, 2017, 9, .	0.6	1
395	Src kinase as a potential therapeutic target in nonâ€alcoholic and alcoholic steatohepatitis. Clinical and Translational Discovery, 2022, 2, .	0.5	1

396 Stealthâ,,¢ Therapeutic Systems: Rationale and Strategies. , 1998, , 25-34.

#	Article	IF	CITATIONS
397	Use of Radiolabeled Liposomes for Imaging of Infection and Inflammation. , 2008, , 237-251.		0
398	Bimodal Liposomes and Paramagnetic QD-Micelles for Multimodality Molecular Imaging of Tumor Angiogenesis. , 2008, , 487-512.		0